Description of a Case of Helicobacter pylori Infection with In Vitro Resistance to Tetracycline: An Exceptional Event with No Consequences?

Microb Drug Resist. 2024 Apr;30(4):164-167. doi: 10.1089/mdr.2023.0247. Epub 2023 Dec 7.

Abstract

Resistance in Helicobacter pylori to tetracycline is rare. We describe the case of an H. pylori strain with a high level of resistance to tetracycline (minimum inhibitory concentration = 12 mg/L). However, despite tetracycline resistance, bismuth quadritherapy was effective. Analysis of the patient's antibiotic treatment history over the previous 25 years revealed repeated 3-month courses of tetracycline for the treatment of acne, suggesting in vivo selection pressure responsible for the emergence of the triple mutation (AGA→TTC) in 16S rDNA associated with tetracycline resistance. This is a rare event but one worth monitoring, especially in view of the widespread use of bismuth quadritherapy for probabilistic treatment in countries where it is available.

Keywords: H. pylori; bismuth; mutation; resistance; tetracycline.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Bismuth / pharmacology
  • Bismuth / therapeutic use
  • Drug Therapy, Combination
  • Helicobacter Infections* / drug therapy
  • Helicobacter pylori* / genetics
  • Humans
  • Metronidazole / pharmacology
  • Microbial Sensitivity Tests
  • Tetracycline / pharmacology
  • Tetracycline / therapeutic use
  • Tetracycline Resistance / genetics

Substances

  • Anti-Bacterial Agents
  • Bismuth
  • Tetracycline
  • Metronidazole